These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

288 related articles for article (PubMed ID: 32246253)

  • 1. GLP-1 receptor agonists in diabetes for stroke prevention: a systematic review and meta-analysis.
    Malhotra K; Katsanos AH; Lambadiari V; Goyal N; Palaiodimou L; Kosmidou M; Krogias C; Alexandrov AV; Tsivgoulis G
    J Neurol; 2020 Jul; 267(7):2117-2122. PubMed ID: 32246253
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Usefulness of Glucagon-Like Peptide-1 Receptor Agonists to Reduce Adverse Cardiovascular Disease Events in Patients with Type 2 Diabetes Mellitus.
    Grewal S; Zaman N; Borgatta L; Nudy M; Foy AJ; Peterson B
    Am J Cardiol; 2021 Sep; 154():48-53. PubMed ID: 34266665
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk of major adverse cardiovascular events and stroke associated with treatment with GLP-1 or the dual GIP/GLP-1 receptor agonist tirzepatide for type 2 diabetes: A systematic review and meta-analysis.
    Stefanou MI; Theodorou A; Malhotra K; Aguiar de Sousa D; Katan M; Palaiodimou L; Katsanos AH; Koutroulou I; Lambadiari V; Lemmens R; Giannopoulos S; Alexandrov AV; Siasos G; Tsivgoulis G
    Eur Stroke J; 2024 Sep; 9(3):530-539. PubMed ID: 38400569
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of glucagon-like peptide-1 receptor agonists on major cardiovascular events in patients with Type 2 diabetes mellitus with or without established cardiovascular disease: a meta-analysis of randomized controlled trials.
    Marsico F; Paolillo S; Gargiulo P; Bruzzese D; Dell'Aversana S; Esposito I; Renga F; Esposito L; Marciano C; Dellegrottaglie S; Iesu I; Perrone Filardi P
    Eur Heart J; 2020 Sep; 41(35):3346-3358. PubMed ID: 32077924
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials.
    Sattar N; Lee MMY; Kristensen SL; Branch KRH; Del Prato S; Khurmi NS; Lam CSP; Lopes RD; McMurray JJV; Pratley RE; Rosenstock J; Gerstein HC
    Lancet Diabetes Endocrinol; 2021 Oct; 9(10):653-662. PubMed ID: 34425083
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a meta-analysis.
    Bethel MA; Patel RA; Merrill P; Lokhnygina Y; Buse JB; Mentz RJ; Pagidipati NJ; Chan JC; Gustavson SM; Iqbal N; Maggioni AP; Öhman P; Poulter NR; Ramachandran A; Zinman B; Hernandez AF; Holman RR;
    Lancet Diabetes Endocrinol; 2018 Feb; 6(2):105-113. PubMed ID: 29221659
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials.
    Kristensen SL; Rørth R; Jhund PS; Docherty KF; Sattar N; Preiss D; Køber L; Petrie MC; McMurray JJV
    Lancet Diabetes Endocrinol; 2019 Oct; 7(10):776-785. PubMed ID: 31422062
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Glucagon-like peptide-1 receptor agonists and cardiovascular outcomes in patients with and without prior cardiovascular events: An updated meta-analysis and subgroup analysis of randomized controlled trials.
    Mannucci E; Dicembrini I; Nreu B; Monami M
    Diabetes Obes Metab; 2020 Feb; 22(2):203-211. PubMed ID: 31595657
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cardiovascular Actions and Clinical Outcomes With Glucagon-Like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors.
    Nauck MA; Meier JJ; Cavender MA; Abd El Aziz M; Drucker DJ
    Circulation; 2017 Aug; 136(9):849-870. PubMed ID: 28847797
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and efficacy of glucagon-like peptide-1 receptor agonists on cardiovascular events in overweight or obese non-diabetic patients.
    Singh S; Garg A; Tantry US; Bliden K; Gurbel PA; Gulati M
    Curr Probl Cardiol; 2024 Mar; 49(3):102403. PubMed ID: 38237815
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Glucagon-like peptide-1 (GLP-1) receptor agonists and cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of double-blind, randomized, placebo-controlled clinical trials.
    Qin J; Song L
    BMC Endocr Disord; 2022 May; 22(1):125. PubMed ID: 35546664
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Glucagon-like peptide-1 receptor agonists and stroke: A systematic review and meta-analysis of cardiovascular outcome trials.
    Adamou A; Barkas F; Milionis H; Ntaios G
    Int J Stroke; 2024 Oct; 19(8):876-887. PubMed ID: 38676552
    [TBL] [Abstract][Full Text] [Related]  

  • 13. GLP-1 Receptor Agonists and Risk of Adverse Cerebrovascular Outcomes in Type 2 Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
    Banerjee M; Pal R; Mukhopadhyay S; Nair K
    J Clin Endocrinol Metab; 2023 Jun; 108(7):1806-1812. PubMed ID: 36800286
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glucagon-Like Peptide-1 Receptor Agonists and Major Adverse Cardiovascular Events in Patients With and Without Diabetes: A Meta-Analysis of Randomized-Controlled Trials.
    Hosseinpour A; Sood A; Kamalpour J; Zandi E; Pakmehr S; Hosseinpour H; Sood A; Agrawal A; Gupta R
    Clin Cardiol; 2024 Jul; 47(7):e24314. PubMed ID: 38953365
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Protection against stroke with glucagon-like peptide 1 receptor agonists: a systematic review and meta-analysis.
    Barkas F; Elisaf M; Milionis H
    Eur J Neurol; 2019 Apr; 26(4):559-565. PubMed ID: 30629331
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cardiovascular outcomes, heart failure and mortality in type 2 diabetic patients treated with glucagon-like peptide 1 receptor agonists (GLP-1 RAs): A systematic review and meta-analysis of observational cohort studies.
    Herrera Comoglio R; Vidal Guitart X
    Int J Clin Pract; 2020 Sep; 74(9):e13553. PubMed ID: 32452094
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Update in Cardiovascular Safety of Glucagon Like Peptide-1 Receptor Agonists in Patients With Type 2 Diabetes. A Mixed Treatment Comparison Meta-Analysis of Randomised Controlled Trials.
    Al Yami MS; Alfayez OM; Alsheikh R
    Heart Lung Circ; 2018 Nov; 27(11):1301-1309. PubMed ID: 29887418
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Glucagon-like peptide-1 receptor agonists and heart failure in type 2 diabetes: systematic review and meta-analysis of randomized and observational studies.
    Li L; Li S; Liu J; Deng K; Busse JW; Vandvik PO; Wong E; Sohani ZN; Bala MM; Rios LP; Malaga G; Ebrahim S; Shen J; Zhang L; Zhao P; Chen Q; Wang Y; Guyatt GH; Sun X
    BMC Cardiovasc Disord; 2016 May; 16():91. PubMed ID: 27169565
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Glucagon-Like Peptide-1 Receptor Agonists and Cardiovascular Risk Reduction in Type 2 Diabetes Mellitus: Is It a Class Effect?
    Li Y; Rosenblit PD
    Curr Cardiol Rep; 2018 Sep; 20(11):113. PubMed ID: 30259238
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of glucagon-like peptide-1 receptor agonists on mortality and cardiovascular events: A comprehensive meta-analysis of randomized controlled trials.
    Monami M; Zannoni S; Pala L; Silverii A; Andreozzi F; Sesti G; Mannucci E
    Int J Cardiol; 2017 Aug; 240():414-421. PubMed ID: 28501352
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.